Global capabilities

This week's research roundup feature: Cytomegalovirus (CMV) is a significant cause of morbidity and mortality among immunocompromised hosts, including transplant recipients. Antiviral prophylaxis or treatment is used to reduce the incidence of CMV disease in this patient population; however, there is concern about increasing antiviral resistance.

In this month's "Hot Topic," Patricia Greipp, D.O., discusses fluorescence in situ hybridization, or FISH testing, particularly related to pediatric patients with hematologic malignancies.

In this episode of “Lab Medicine Rounds,” host Justin Kreuter, M.D., speaks with Timothy Wiltshire, Ph.D., assistant professor of laboratory medicine and pathology in the division of transfusion medicine to discuss what’s new with CAR-T cells.

This page includes updates posted to Mayo Clinic Labs during the month of October.

In this episode of “Answers From the Lab,” host Bobbi Pritt, M.D., chair of the Department of Laboratory Medicine and Pathology at Mayo Clinic, is joined by William Morice II, M.D., Ph.D., CEO and president of Mayo Clinic Laboratories. They discuss the recent news of a possible cure for sickle cell disease, as well as gene editing therapies and their impact on the laboratory.

This week's research roundup feature: It is widely held that heart failure (HF) does not cause exertional hypoxaemia, based upon studies in HF with reduced ejection fraction, but this may not apply to patients with HF and preserved ejection fraction (HFpEF). Here, we characterize the prevalence, pathophysiology, and clinical implications of exertional arterial hypoxaemia in HFpEF.

In this episode of Mayo Clinic Laboratories’ “Leveraging the Laboratory” podcast, host Jane Hermansen, outreach manager at Mayo Clinic Laboratories, talks with outreach solutions strategists Ellen Dijkman Dulkes and Brianne Newton about creating a positive customer service experience in the outreach laboratory.

In this episode of “Answers From the Lab,” host Bobbi Pritt, M.D., chair of the Department of Laboratory Medicine and Pathology at Mayo Clinic, is joined by William Morice II, M.D., Ph.D., CEO and president of Mayo Clinic Laboratories, to discuss the role and expansion of at-home testing.

The nonprofit patient advocacy group called The MOG Project supports patients with myelin oligodendrocyte glycoprotein antibody-associated disease (MOGAD), which is a rare and debilitating central nervous system demyelinating disorder. A team of Mayo Clinic neurologists, neuro-ophthalmologists, and the Autoimmune Neurology Laboratory at Mayo Clinic share a unique relationship with The MOG Project as they harness the power of patients’ experiences with MOGAD and their biospecimen data to advance the science behind this disease.

The United States will observe the Thanksgiving holiday on Thursday, Nov. 23. On this day, Mayo Clinic Laboratories will be open; however, specimen shipments and deliveries to our laboratories will not be made by the carriers. To safeguard specimens, please follow these shipping recommendations.

This week's research roundup feature: Renal fibrosis is now recognized as a main determinant of renal pathology to include chronic kidney disease. Deposition of pathological matrix in the walls of glomerular capillaries, the interstitial space, and around arterioles predicts and contributes to the functional demise of the nephron and its surrounding vasculature.

Patients want to use a laboratory that is easy to work with, and there are different definitions of “easy.” Ultimately, health systems want to have the patients they serve use their health system laboratories. If patients are choosing to go elsewhere, the laboratory should review and respond to several key patient experience factors.